Lv1
92 积分 2021-07-19 加入
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
3天前
已完结
Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration
16天前
已完结
Abstract 450: JZY-2233: An antigen-targeted CBP/p300 degrader-antibody conjugate for advanced prostate cancer therapy
17天前
已关闭
911 Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
17天前
已完结
Molecular glue meets antibody: next-generation antibody–drug conjugates
22天前
已完结
Mechanisms of resistance to antibody–drug conjugates in cancers
22天前
已完结
Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan
23天前
已完结
81 (PB069): A novel BRD4 degrader, MT-4561, exerts continuous anti-tumor effects in various cancer xenograft model and patient derived cells
27天前
已完结
Genetic mutations and inhibitors of p300 and CBP
29天前
已关闭
Animal models of colorectal cancer with liver metastasis
1个月前
已完结
皖公网安备34019202002308
